[Newsmp] Japanese pharmaceutical companies operating in Korea all ramped up their retained earnings last year.
The audit reports showed that the retained earnings of the nine Japanese pharmaceutical companies’ Korean offshoots have increased.
Among them, Eisai Korea saw its retained earnings rise by KRW 16.7 billion, the largest increase despite the decrease in sales last year.
Otsuka Korea, which has the largest retained earnings among the nine companies, also increased by KRW 16.1 billion to reach KRW 250 billion.
During the same period, Santen Korea also rose by KRW 12.3 billion, expanding retained earnings of three companies by more than KRW 10 billion.
Astellas Pharma Korea marked an increase of KRW 9.2 billion, followed by Daiichi Sankyo Korea (KRW 8.5 billion), Takeda Korea (KRW 4.1 billion), Mitsubishi Tanabe Pharma (KRW 3.2 billion), Ono Pharma Korea (KRW 2.2 billion), and Kyowa Kirin Korea (KRW 1.6 billion).
Otsuka Korea was the only company to exceed KRW 200 billion with KRW 249 billion in retained earnings at the end of the 2021 fiscal year, and Eisai Korea almost reached KRW 150 billion with KRW 143.8 billion.
Astellas Pharma Korea recorded KRW 74.4 billion, Daiichi Sankyo Korea KRW 70.6 billion, and Santen Korea KRW 61.3 billion, exceeding KRW 50 billion.
Moreover, Kyowa Kirin Korea, Mitsubishi Tanabe Pharma, and Ono Pharma Korea entered the KRW 10 billion mark with KRW 38.1 billion, KRW 27.4 billion, and KRW 10.2 billion.
